XTX Topco Ltd Takes $597,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

XTX Topco Ltd acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,223 shares of the biopharmaceutical company's stock, valued at approximately $597,000.

Other large investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC grew its holdings in shares of PTC Therapeutics by 78.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 613 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 270 shares during the last quarter. Sterling Capital Management LLC increased its holdings in shares of PTC Therapeutics by 424.4% in the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 522 shares during the period. Venturi Wealth Management LLC acquired a new position in shares of PTC Therapeutics in the fourth quarter valued at approximately $68,000. R Squared Ltd acquired a new position in shares of PTC Therapeutics in the fourth quarter valued at approximately $79,000. Finally, KBC Group NV increased its holdings in shares of PTC Therapeutics by 36.4% in the fourth quarter. KBC Group NV now owns 3,045 shares of the biopharmaceutical company's stock valued at $137,000 after purchasing an additional 813 shares during the period.

PTC Therapeutics Stock Performance

NASDAQ PTCT traded down $0.62 during trading hours on Thursday, hitting $49.33. 119,397 shares of the company's stock were exchanged, compared to its average volume of 808,737. The business's 50 day moving average is $50.11 and its 200-day moving average is $46.36. PTC Therapeutics, Inc. has a 12-month low of $24.00 and a 12-month high of $58.38. The firm has a market capitalization of $3.89 billion, a P/E ratio of -8.30 and a beta of 0.58.

Analyst Ratings Changes

PTCT has been the topic of a number of recent research reports. Bank of America raised PTC Therapeutics from an "underperform" rating to a "neutral" rating and boosted their target price for the company from $41.00 to $55.00 in a report on Tuesday, March 11th. Royal Bank of Canada restated an "outperform" rating and issued a $65.00 price target on shares of PTC Therapeutics in a research note on Tuesday. Morgan Stanley restated an "overweight" rating and issued a $70.00 price target (up from $67.00) on shares of PTC Therapeutics in a research note on Friday, March 7th. JPMorgan Chase & Co. decreased their price target on PTC Therapeutics from $78.00 to $75.00 and set an "overweight" rating on the stock in a research note on Monday, March 31st. Finally, Citigroup upped their target price on PTC Therapeutics from $32.00 to $45.00 and gave the company a "sell" rating in a report on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, PTC Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $63.92.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 1,333 shares of the company's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $50.10, for a total value of $66,783.30. Following the completion of the transaction, the vice president now owns 105,515 shares in the company, valued at $5,286,301.50. This represents a 1.25 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Lee Scott Golden sold 897 shares of PTC Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total transaction of $42,114.15. Following the sale, the executive vice president now owns 75,997 shares in the company, valued at $3,568,059.15. This represents a 1.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 29,501 shares of company stock worth $1,546,088 in the last three months. 5.50% of the stock is currently owned by company insiders.

PTC Therapeutics Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.